MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 592767 | Name: Ambasilide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ambasilide is a Class III antiarrhythmic agent.

Chemical Structure

Ambasilide
Ambasilide
CAS#83991-25-7

Theoretical Analysis

MedKoo Cat#: 592767

Name: Ambasilide

CAS#: 83991-25-7

Chemical Formula: C21H25N3O

Exact Mass: 335.1998

Molecular Weight: 335.45

Elemental Analysis: C, 75.19; H, 7.51; N, 12.53; O, 4.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Ambasilide; Ambasilidum
IUPAC/Chemical Name
3-(p-Aminobenzoyl)-7-benzyl-3,7-diazabicyclo(3.3.1)nonane
InChi Key
DLNAKYFPFYUBDR-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H25N3O/c22-20-8-6-19(7-9-20)21(25)24-14-17-10-18(15-24)13-23(12-17)11-16-4-2-1-3-5-16/h1-9,17-18H,10-15,22H2
SMILES Code
O=C(N1CC(C2)CN(CC3=CC=CC=C3)CC2C1)C4=CC=C(N)C=C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 335.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bosch RF, Milek IV, Popovic K, Mermi J, Mewis C, Kühlkamp V, Seipel L. Ambasilide prolongs the action potential and blocks multiple potassium currents in human atrium. J Cardiovasc Pharmacol. 1999 May;33(5):762-71. PubMed PMID: 10226864. 2: Koidl B, Flaschberger P, Schaffer P, Pelzmann B, Bernhart E, Mächler H, Rigler B. Effects of the class III antiarrhythmic drug ambasilide on outward currents in human atrial myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):226-32. PubMed PMID: 8717164. 3: Baláti B, Iost N, Simon J, Varró A, Papp JG. Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agent, in canine isolated ventricular muscle and purkinje fibers. Gen Pharmacol. 2000 Feb;34(2):85-93. PubMed PMID: 10974415. 4: Kijtawornrat A, Hamlin RL, Hamlin DM. Effects of ambasilide in isolated perfused guinea pig heart: use dependence. Cardiovasc Toxicol. 2005;5(1):53-62. PubMed PMID: 15738585. 5: Walker BD, Singleton CB, Tie H, Bursill JA, Wyse KR, Valenzuela SM, Breit SN, Campbell TJ. Comparative effects of azimilide and ambasilide on the human ether-a-go-go-related gene (HERG) potassium channel. Cardiovasc Res. 2000 Oct;48(1):44-58. PubMed PMID: 11033107. 6: Schreieck J, Wang Y, Gjini V, Korth M, Zrenner B, Schömig A, Schmitt C. Differential effect of beta-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol. 1997 Dec;8(12):1420-30. PubMed PMID: 9436780. 7: Villa S, Barlocco D, Cignarella G, Papp GJ, Baláti B, Takács J, Varró A, Borosy A, Keserû K, Mátyus P. 3,8-diazabicyclo--[3.2.1]-octane derivatives as analogues of ambasilide, a Class III antiarrhythmic agent. Eur J Med Chem. 2001 Jun;36(6):495-506. PubMed PMID: 11525840. 8: Stramba-Badiale M, Pessano P, Kirchengast M, Schwartz PJ. Effects of the potassium channel blocking agent ambasilide on ventricular arrhythmias induced by acute myocardial ischemia and sympathetic activation. Am Heart J. 1995 Mar;129(3):549-56. PubMed PMID: 7872187. 9: Takanaka C, Sarma JS, Singh BN. Electrophysiologic effects of ambasilide (LU 47110), a novel class III antiarrhythmic agent, on the properties of isolated rabbit and canine cardiac muscle. J Cardiovasc Pharmacol. 1992 Feb;19(2):290-8. PubMed PMID: 1376799. 10: Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between d-sotalol and the new antiarrhythmic drug ambasilide. Circulation. 1994 Oct;90(4):2032-40. PubMed PMID: 7923691. 11: Yue L, Feng JL, Wang Z, Nattel S. Effects of ambasilide, quinidine, flecainide and verapamil on ultra-rapid delayed rectifier potassium currents in canine atrial myocytes. Cardiovasc Res. 2000 Apr;46(1):151-61. PubMed PMID: 10727663. 12: Zhang ZH, Follmer CH, Sarma JS, Chen F, Singh BN. Effect of ambasilide, a new class III agent, on plateau currents in isolated guinea pig ventricular myocytes: block of delayed outward potassium current. J Pharmacol Exp Ther. 1992 Oct;263(1):40-8. PubMed PMID: 1403801. 13: Feng J, Wang Z, Li GR, Nattel S. Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther. 1997 Apr;281(1):384-92. PubMed PMID: 9103521. 14: Weyerbrock S, Schreieck J, Karch M, Overbeck M, Meisner H, Kemkes B, Schömig A, Schmitt C. Rate-independent effects of the new class III antiarrhythmic agent ambasilide on transmembrane action potentials in human ventricular endomyocardium. J Cardiovasc Pharmacol. 1997 Nov;30(5):571-5. PubMed PMID: 9388038. 15: Zaza A, Malfatto G, Schwartz PJ. Effects on atrial repolarization of the interaction between K+ channel blockers and muscarinic receptor stimulation. J Pharmacol Exp Ther. 1995 Jun;273(3):1095-104. PubMed PMID: 7791080. 16: Gjini V, Korth M, Schreieck J, Weyerbrock S, Schömig A, Schmitt C. Differential class III antiarrhythmic effects of ambasilide and dofetilide at different extracellular potassium and pacing frequencies. J Cardiovasc Pharmacol. 1996 Aug;28(2):314-20. PubMed PMID: 8856489. 17: Mehdirad AA, Carnes CA, Nelson SD. The influence of specific and nonspecific potassium current blockade on the defibrillation energy requirement of biphasic shock. Pacing Clin Electrophysiol. 1999 Jan;22(1 Pt 2):147-51. PubMed PMID: 9990620. 18: Capucci A, Aschieri D, Villani GQ, Piepoli MF. Clinical potential of emerging antiarrhythmic agents. Drugs R D. 1999 Apr;1(4):279-90. Review. PubMed PMID: 10566046. 19: Lombardi F, Terranova P. Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. Curr Med Chem. 2006;13(14):1635-53. Review. PubMed PMID: 16787210. 20: Dorian P. Mechanisms of action of class III agents and their clinical relevance. Europace. 2000 Jul;1 Suppl C:C6-9. Review. PubMed PMID: 11220521.